DÄ internationalArchive48/2006Pathogenic, Clinical, Diagnostic and Therapeutic Aspects of Posttransplantation Lymphoproliferative Disorders

Review article

Pathogenic, Clinical, Diagnostic and Therapeutic Aspects of Posttransplantation Lymphoproliferative Disorders

Dtsch Arztebl 2006; 103(48): A-3259

Trappe, R; Oertel, S; Riess, H

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Babcock GJ, Decker LL, Freeman RB et al.: Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999; 4: 567–76. MEDLINE
2. Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 20: 1413–21. MEDLINE
3. Bakker NA, van Imhoff GW, Verschuuren EA et al.: Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 3: 327–34. MEDLINE
4. Harris NL, Ferry JA, Swerdlow SH: Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 1: 8–14. MEDLINE
5. Leblond V, Dhedin N, Mamzer Bruneel MF et al.: Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001; 3: 772–8. MEDLINE
6. Tsai DE, Hardy CL, Tomaszewski JE et al.: Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 8: 1076–88. MEDLINE
7. Leblond V, Davi F, Charlotte et al.: Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 6: 2052–9. MEDLINE
8. Trappe R, Oertel SH, Choquet S et al.: Sequential treatment with the anti-CD 20 antibody rituximab and CHOP+GCSF chemotherapy in patients with post-transplant lymphoproliferative disorder (PTLD): First results of a multicenter phase II study. Blood 2005; 11: 274a.
9. Starzl TE, Nalesnik MA, Porter KA et al.: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 8377: 583–7. MEDLINE
10. Allen U, Hebert D, Moore D et al.: Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988–97: a Canadian multi-centre experience. Pediatr Transplant 2001; 3: 198–203. MEDLINE
11. Swinnen LJ: Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000; 11 Suppl 1: 45–8. MEDLINE
12. Oertel S, Trappe RU, Zeiderl K et al.: Epstein-Barr virus DNA in blood samples of adults with post-transplant lymphoproliferative disease does not correlate with clinical course. Ann Hematol 2006; 85: 478–84. MEDLINE
13. Mentzer SJ, Perrine SP, Faller DV: Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis 2001; 3: 177–85. MEDLINE
14. Oertel SH, Anagnostopoulos I, Hummel MW et al.: Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 2002; 4: 1120–3. MEDLINE
15. Davis CL, Wood BL, Sabath DE et al.: Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 12: 1770–9. MEDLINE
16. Haddad E, Paczesny S, Leblond V et al.: Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001; 6: 1590–7. MEDLINE
17. Comoli P, Maccario R, Locatelli F et al.: Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 6: 1415–22. MEDLINE
18. Oertel SH, Verschuuren E, Reinke P et al.: Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 12: 2901–6. MEDLINE
19. Choquet S, Leblond V, Herbrecht R et al.: Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase II study. Blood 2006; 107: 3053–7. MEDLINE
20. Suryanarayan K, Natkunam Y, Berry G et al.: Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. J Pediatr Hematol Oncol 2001; 7: 452–55. MEDLINE
21. Caillard S, Lachat V, Moulin B: Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group. Transpl Int 2000; 13 Suppl 1: 388–93. MEDLINE
22. Pickhardt PJ and Siegel MJ: Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients. Radiology 1999; 1: 73–8. MEDLINE
23. Wu L, Rappaport DC, Hanbidge A et al.: Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging 2001; 2: 200–206. MEDLINE
24. Beynet DP, Wee SA, Horwitz SS et al.: Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Arch Dermatol 2004; 9: 1140–6.
e1. Birkeland SA, Andersen HK, Hamilton-Dutoit SJ: Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 9: 1209–14.
e2. Gao SZ, Chaparro SV, Perlroth M et al.: Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003; 5: 505–14.
e3. Cesarman E, Chadburn A, Liu YF et al.: BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 7: 2294–302.
e4. Knowles DM, Cesarman E, Chadburn A et al.: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 2: 552–65.